US pharmaceutical company Pfizer’s new global drug development center in Chennai will play a major role in its plan to introduce 25 therapies internationally by 2025, with a particular focus on hospital products and oncology . More than 250 scientists and laboratory technicians involved in pharmaceutical research and development work at IIT Madras Research Park to develop innovative formulations and APIs for the global market.
S Sridhar, Country Director of Pfizer India, told FE: “Globally, we expect to introduce 25 new therapies by 2025. The work of this center can serve many of these therapeutic areas. The center also provides technical support for products that are already on the market.
The Chennai factory team works closely with several manufacturing centers and partners to provide technical advice and help optimize manufacturing processes taking into account technical, quality and safety parameters.
“Products developed at the Chennai center could be transferred to any manufacturing facility globally within the Pfizer network, depending on product requirements, including our Vizag facility, our joint venture facility in Ahmedabad or our manufacturing partners. Sridhar said.
According to him, bringing new medicines or drugs to market is a long and complex process that requires the completion of many stages of work. Much of this work is carried out at the center in Chennai, the first and only facility in Asia allowing Pfizer to develop products for global markets and support its manufacturing units around the world.
As is well known, Pfizer recently established a global drug development facility to accelerate its path to achieving breakthroughs that change the lives of patients. The center spans 61,000 square feet and houses 10 labs, workstations, and large and medium-sized conference rooms. The facility’s capabilities will include the development of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) of differentiated products such as value-added complex formulations, controlled release dosage forms, device combination products, lyophilized injections, powdered fillers, and ready-to-use formulations. Pfizer has invested $20 million (Rs 150 crore) in the unit and it will be part of a network of 12 global centers.
The facility will employ 250 scientists and professionals from a variety of scientific disciplines, including formulation scientists and pharmacists, analytical scientists specializing in analytical and formulation medical sciences, life science specialists, chemical engineers, data scientists and program managers.